Search

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sarepta Therapeutics to Present at the BofA Securities Health Care Conference
Sarepta Therapeutics to Announce First Quarter 2025 Financial Results
Sarepta Therapeutics Provides Update on ELEVIDYS
Sarepta Corporate Fact Sheet
Sarepta Therapeutics Announces Approval in Japan of ELEVIDYS, a Gene Therapy to Treat Duchenne Muscular Dystrophy
Sarepta Therapeutics Shares New Protein Expression and Safety Results from ENDEAVOR in Participants 2 Years Old at Time of Treatment
Sarepta Therapeutics Presents Data at the American Society of Gene & Cell Therapy Conference, Including Statistically Significant Functional Outcomes for 8- and 9-Year-Old Patients in New Data Analysis of EMBARK Part 2
Wearable devices and the future of rare disease clinical trials: Landry’s story
Video: Scholarship Recipients, and Twins, Austin and Connor Travel Route 79 Together